Loading clinical trials...
Loading clinical trials...
A randomized, placebo-controlled, double-blind clinical trial of effect of allopurinol or febuxostat to prevent contrast induced acute kidney injury (CI-AKI)
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
Collaborators
NCT04936607 · Contrast-Induced Acute Kidney Injury
NCT07231939 · Coronary Artery Disease, Acute Kidney Injury, and more
NCT05283512 · Contrast-induced Nephropathy, Kidney Injury, and more
NCT06429345 · Contrast-induced Nephropathy
NCT04864847 · Acute Kidney Injury, Contrast-induced Nephropathy
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, México City
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions